u/rafael_sjoberg

a liver endpoint is not a weight endpoint with better marketing

Adding the one process step — write down where you are before you change anything.

Disagreeing with this bit: stretching and reducing are different things and the post treats them as one.

Correcting myself upthread: appetite returned at week 12 for me, not the week I posted.

That is a pause rather than a stop, and the plans for the two are not the same.

Wrote down where I was before changing anything. That single page made the following six months interpretable.

Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.

stretching to ten days then twelve is the pattern people report

This is the sentence that reframes the whole board. Appetite first, scale later.

watch appetite, not the scale, for the first month

Small fix — you have described interval stretching and called it a taper. The exposure profiles differ.

Appetite is the proximal effect and weight is the lagging integrated outcome, which is why watching appetite gives you an earlier and more honest signal.

Right, and the trial titration was slow for reasons that are visible in the tolerability tables.

I would not treat appetite returning as a sign of doing it wrong. It is the expected sequence.

It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.

That figure is from the obesity programme, and this thread is about the hepatic one.

A written baseline — dose, date, weight, waist, and how appetite feels — taken before any change is what makes the following months interpretable rather than a series of impressions.

Nothing on this board is a taper schedule, and no member can write one for another. What can be shared is what people watched and what they observed.

research material is not approved for human use, which is why the clinical record here is thin

Agreed. The hepatic programme is the point of this compound and the weight discussion is a side effect of the side effect.

Right, and the habits from the losing phase are the part that has to outlive the dose.

the titration in the trials was slow and deliberate

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.